Tislelizumab - Beigene

Drug Profile

Tislelizumab - Beigene

Alternative Names: BGB-A317

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Celgene Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fc receptor modulators; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer
  • Phase II Gastric cancer; Hodgkin's disease; Lung cancer; Lymphoma; Urogenital cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 10 Apr 2018 Phase-II clinical trials in Hepatocellular carcinoma (Inoperable/Unresectable, Second-line therapy or greater) in China, Taiwan, USA, Europe (IV)
  • 19 Mar 2018 Phase-II clinical trials in Lymphoma (Second-line therapy or greater) in China (IV) (NCT03493451)
  • 28 Feb 2018 BeiGene plans to submit first NDA in China for Hodgkin’s lymphoma in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top